Results, of a study published in the Journal of Cosmetic Dermatology in May, 2019, showed human umbilical cord derived Wharton’s jelly mesenchymal stem cells can accelerate the repair and healing of chronic skin ulcers. Diabetic skin ulcers are painful, slow to heal, and require medical attention.
Consistently high levels of blood sugar cause nerve and blood vessel damage, reduce circulation, and alter the skin’s structure causing harmless wounds to become open sores called diabetic ulcers. If left untreated, diabetic skin ulcers can become infected causing tissue death and ultimately require amputation.
A diabetic ulcer is an open sore or wound and most commonly presents on the foot that does not progress through the normal healing process. Approximately 15% of patients with diabetes will develop a foot ulcer and approximately 6% of people will require hospitalization due to an infection or other wound related complication.
Researchers at Shiraz University of Medical Sciences in Shiraz, Iran evaluated the effectiveness of umbilical cord Wharton’s jelly stem cells to heal chronic diabetic skin ulcers.
Study Design
The study was a randomized trial of five patients between the ages of 30 and 60 years, with chronic diabetic ulcers. Clinicians used acellular amniotic membrane with Wharton’s jelly mesenchymal stem cells to cover the wounds for 9 days. Patients were followed every three days over the 9 days and then 1-month post treatment. Researchers documented the percentage of wound healing, and the size of the wound.1
Study Results
At 6 and 9 days, the wound of patients receiving stem cell treatment healed more quickly and the size of the wound decreased significantly more than patients not treated with stem cell therapy.
Stem cell therapy at the Stem Cells Transplant Institute
Stem cell therapy at the Stem Cells Transplant Institute can help improve the signs and symptoms of diabetes, including diabetic ulcers.
Treatment at the Stem Cells Transplant Institute could help improve the following symptoms of diabetes:
- Excessive thirst
- Frequent Urination
- Excessive hunger
- Fatigue
- Blurred Vision
- Unexplained weight loss
- Irritability
- Frequent infections
- Slow healing sores (e.g. diabetic ulcers, gum infections, vaginal infections)
- Dizziness
Stem cell therapy for the treatment of type 2 diabetes
Mesenchymal stem cells have the ability to:
- Differentiate into insulin producing cells
- Regenerate and protect pancreatic cells
- Restore beta cell function and mass
- Convert alpha cell to beta cells
- Reduce inflammation and insulin resistance
Treatment Protocol at the Stem Cells Transplant Institute
For optimal results, the Stem Cells Transplant Institute recommends a one-day treatment with human umbilical cord stem cells (hUC-MSCs) for the treatment of type 2 diabetes. Treatment also includes:
- Antioxidant therapy with vitamin C and glutathione
- Ozone therapy
- Platelet-rich plasma therapy (PRP)
The advantages of human umbilical cord mesenchymal stem cells
- Abundant supply containing up to 10 times more stem cells than bone marrow or adipose derived stem cells
- hUC-MSC have immunosuppressors and immunomodulatory properties that allow their use in any individual without rejection- Human Leukocyte Antigen (HLA) matching is not necessary
- Greater proliferation ability than adult autologous stem cells
- They regenerate at a very rapid rate
- They are young and very adaptive
- They have not been impacted by the aging process
- They have not been affected by environmental toxins
- Umbilical cord stem cells can be administered multiple times over the course of days
- Eliminates the need to collect stem cells from the patient’s fat or hip bone reducing pain and recovery time
If you, or someone you love, suffer from chronic diabetic ulcers or other symptoms of type 2 diabetes, contact the Stem Cells Transplant Institute to learn more about the benefits of stem cell therapy.
Scientific Reference:
- Hashemi SS, et. al., The healing effect of Wharton’s jelly stem cells seeded on biological scaffold in chronic skin ulcers: A randomized clinical trial. J Cosmet Dermatol.2019 May 24. doi: 10.1111/jocd.12931.
